KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
0.261
-0.018 (-6.33%)
At close: Mar 9, 2026, 4:00 PM EDT
0.267
+0.006 (2.34%)
After-hours: Mar 9, 2026, 7:11 PM EDT
KALA BIO Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
7.36M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bolt Biotherapeutics | 5.20M |
| CollPlant Biotechnologies | 2.48M |
| Iterum Therapeutics | 390.00K |
| Addex Therapeutics | 198.82K |
| Kiora Pharmaceuticals | 20.00K |
| Alaunos Therapeutics | 6.00K |
| Pulmatrix | 3.00K |
| Ernexa Therapeutics | 1,000.00 |
KALA News
- 13 hours ago - Stock Trend Capital Provides Younet AI Investment Update - Newsfile Corp
- 5 days ago - KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency” - GlobeNewsWire
- 2 months ago - KALA BIO Settles Approximately $10.6 million of Debt - GlobeNewsWire
- 3 months ago - KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 5 months ago - Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday? - Benzinga
- 7 months ago - KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewsWire
- 8 months ago - KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) - GlobeNewsWire